We previously reported that the *ApoE* e4e4 genotype was associated with COVID-19 test positivity (odds ratio \[OR\] = 2.31, 95% CI: 1.65--3.24, *p* = 1.19 × 10^−6^) ([@CIT0001]) in the UK Biobank (UKB) cohort, during the epidemic peak in England, from March 16 to April 26, 2020 ([@CIT0002]). With more COVID-19 test results (March 16 to May 31, 2020) and mortality data (to March 31, 2020, with incomplete data for April 2020) linked to UKB, we reevaluated the *ApoE* e4 allele association with COVID-19 test positivity, and with all-cause mortality following test-confirmed COVID-19.

We restricted analyses to European-ancestry participants ([@CIT0003]) (*n* = 451 367, 90% of sample) attending baseline assessment centers in England (*n* = 398 073) and excluded participants who died before the pandemic (set at February 1, 2020, *n* = 22 384). Single-nucleotide polymorphism data for rs429358 and rs7412 were used to determine *ApoE* genotypes. Our outcomes of interest were: (a) COVID-19 test positive versus the rest of the sample meeting inclusion criteria (ie, including untested samples and tested negative), and (b) tested positive and died versus the rest of the sample as above, but with additional exclusion of test positive participants who survived. Some of the excluded samples could have died but cannot be identified due to incomplete mortality data for April 2020. Logistic regression models compared *ApoE* e4e4 participants (or e3e4s) to e3e3s with adjustment for sex; age on April 26 or age at death; baseline UKB assessment center in England (accounting for geographical differences in viral exposures); genotyping array type; and the top five genetic principal components (accounting for possible population admixture).

The mean attained age was 68.2 years (*SD* = 8.0) with 174 667 females (55%). Of 219 747 e3e3 participants, 663 participants tested positive (302 per 100 000), of whom, 79 later died. Similarly, of 8767 e4e4 participants, 59 tested positive (673 per 100 000), of whom 13 later died ([Table 1](#T1){ref-type="table"}). In logistic models, *ApoE* e4e4 genotype was associated with increased risks of test positivity (OR = 2.24, 95% CI: 1.72--2.93, *p* = 3.24 × 10^−9^) and of mortality with test-confirmed COVID-19 (OR = 4.29, 95% CI: 2.38--7.72, *p* = 1.22 × 10^−6^), compared to e3e3s. For e3e4s versus e3e3s, these two associations were nominally statistically significant (at *p* \< .05), but with much smaller effect sizes. The e4e4 associations were similar after excluding 50 566 participants related to the third degree or closer for test positivity (e4e4 OR = 2.30, 95% CI: 1.73--3.07, *p* = 1.39 × 10^−8^) and for mortality with test-confirmed COVID-19 (e4e4 OR = 4.53, 95% CI: 2.39--8.61, *p* = 3.87 × 10^−6^). Additionally, the e4e4 association with either COVID-19 outcome was little changed after removing participants with diseases associated with *ApoE* e4 alleles ([@CIT0004]) and COVID-19 severity ([@CIT0005]), including dementia, hypertension, coronary artery disease (myocardial infarction or angina), or type 2 diabetes ([Table 1](#T1){ref-type="table"}), based on diagnoses recorded from baseline self-reports and hospital discharge records during follow-up to March 2017. *ApoE* e3e4s were modestly associated with test positivity overall, and the association tended to be less marked in disease-free samples ([Table 1](#T1){ref-type="table"}). In additional analyses, we tested associations with *ApoE* e2 alleles, which have been linked to beneficial health outcomes ([@CIT0004]). No associations were found between e2e3 and either of our COVID-19 outcomes (*p* \> .05, vs e3e3). Analyses for e2e2s associations were underpowered (*n* = 2427, 4 positives, and 1 positive death).

###### 

Risk of COVID-19 Test Positivity and Mortality, Comparing Participants With *ApoE* e3e4 or e4e4 to e3e3 Genotypes, in UK Biobank

                                                                                 COVID-19 Positive vs Rest of Study Sample             COVID-19 Positive and Died vs Rest^†^ of Study Sample   
  ----------------------------------- --------- --------- ----- ---- ----- ----- ------------------------------------------- --------- ------------------------------------------------------- ---------
  All                                                                                                                                                                                          
   e3e3                               219 747   219 084   663   79   302   36                                                                                                                  
   e3e4                               88 882    88 561    321   42   361   47    1.20 (1.05, 1.37)                           .009      1.35 (0.92, 1.96)                                       .121
   e4e4                               8767      8708      59    13   673   148   2.24 (1.72, 2.93)                           3.24E-9   4.29 (2.38, 7.72)                                       1.22E-6
  Excluding dementia                                                                                                                                                                           
   e3e3                               219 392   218 744   648   76   295   35                                                                                                                  
   e3e4                               88 558    88 263    295   34   333   39    1.13 (0.98, 1.29)                           .093      1.14 (0.76, 1.70)                                       .536
   e4e4                               8676      8618      58    13   669   151   2.27 (1.74, 2.98)                           2.42E-9   4.53 (2.51, 8.16)                                       5.21E-7
  Excluding hypertension                                                                                                                                                                       
   e3e3                               147 332   146 958   374   31   254   21                                                                                                                  
   e3e4                               59 655    59 483    172   17   288   29    1.13 (0.94, 1.35)                           .186      1.39 (0.77, 2.51)                                       .278
   e4e4                               5918      5881      37    5    625   85    2.45 (1.75, 3.44)                           2.10E-7   4.25 (1.65, 10.95)                                      .003
  Excluding coronary artery disease                                                                                                                                                            
   e3e3                               201 003   200 435   568   62   283   31                                                                                                                  
   e3e4                               80 850    80 590    260   33   322   41    1.14 (0.98, 1.32)                           .090      1.36 (0.89, 2.08)                                       .153
   e4e4                               7973      7923      50    10   627   126   2.23 (1.67, 2.98)                           6.21E-8   4.23 (2.16, 8.26)                                       2.43E-5
  Excluding type 2 diabetes                                                                                                                                                                    
   e3e3                               208 374   207 795   579   61   278   29                                                                                                                  
   e3e4                               84 620    84 342    278   30   329   36    1.18 (1.02, 1.36)                           .024      1.24 (0.80, 1.92)                                       .338
   e4e4                               8 391     8336      55    12   655   144   2.36 (1.79, 3.12)                           1.23E-9   5.05 (2.72, 9.39)                                       3.08E-7

*Notes*: CI = confidence interval; OR = odds ratio.

\*Adjusted for sex, age at death or age on April 26, 2020 (the last date of death), assessment center in England, genotyping array type, and the top five genetic principal components.

^†^Comparison group excluded participants testing positive and surviving.

The results presented imply a recessive effect of the *ApoE* e4 allele. Only modest associations were present between the much more common e3e4 genotype and COVID-19 outcomes, similar to results for rs429358 (which separates 0, 1, and 2 copies of e4 alleles, OR = 1.3, *p* = .0026) reported for severe COVID-19 with respiratory failure in a recent additive effect genome-wide analysis ([@CIT0006]). *ApoE* e4e4 associations with test positivity and mortality were little affected by excluding dementia and other *ApoE* e4-associated diagnoses reported before March 2017: future work should include recent preexisting diagnoses. More data are needed on *ApoE* and COVID-19 associations in other ancestry groups, as numbers of UKB participants of such groups are unfortunately too small for this analysis.

In conclusion, *ApoE* e4e4 genotype is associated with COVID-19 test positivity at genome-wide significance (ie, *p* \< 5 × 10^−8^) in UKB, using data covering a longer period than previously reported. Similarly, the e4e4 genotype was associated with a 4-fold increase in mortality after testing positive for COVID-19, in UKB. Independent replications are needed to confirm our findings and mechanistic work is needed to understand how *ApoE* e4e4 results in the marked increase in vulnerability, especially for COVID-19 mortality. These findings also demonstrate that risks for COVID-19 mortality are not simply related to advanced chronological age or the comorbidities commonly seen in aging.
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